10-K: Sonendo, Inc. Files 10-K for Fiscal Year 2024, Suspends SEC Reporting

Sonendo, Inc. reports its 2024 financial results, including a net loss of $33.5 million, and announces the suspension of its SEC reporting obligations.

Summary

• Sonendo, Inc., a medical technology company focused on treating tooth decay, filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The company reported revenue of $31.7 million and a net loss of $33.5 million from continuing operations for 2024, compared to revenue of $34.6 million and a net loss of $62.5 million in 2023.
• As of December 31, 2024, Sonendo had $11.6 million in cash and cash equivalents and short-term investments, an accumulated deficit of $458.0 million, and $15.1 million in principal outstanding under its term loan facility.
• The company divested its Software segment in March 2024 for approximately $16.0 million, recording a gain of $5.7 million on the sale.
• Effective January 1, 2025, the American Dental Association (ADA) updated ADA Code 2940 to clarify that it should also be used to create an endodontic seal, which may benefit the GentleWave procedure.
• In February 2025, Sonendo amended its credit agreement, deferring and waiving certain amortization payments subject to conditions including near-term equity financings.
• Sonendo's common stock was delisted from the NYSE in April 2024 and subsequently moved from the OTCQX to the OTC Pink market in February 2025.
• The company has decided to voluntarily suspend its reporting obligations with the SEC and will no longer file periodic reports.
• This Form 10-K is the last report that the Company anticipates filing with the SEC.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company reduced its net loss, revenue declined, and it faces significant financial challenges, including the need for additional funding and delisting from major exchanges. The suspension of SEC reporting adds further uncertainty.

Positives

• The company's net loss decreased significantly in 2024 compared to 2023.
• The divestiture of the Software segment generated a gain of $5.7 million.
• The credit agreement amendment provides some financial flexibility in the near term.
• The ADA updated ADA Code 2940, which may improve insurance reimbursement for the GentleWave procedure.

Negatives

• Revenue decreased in 2024 compared to 2023.
• The company has an accumulated deficit of $458.0 million.
• Sonendo's common stock was delisted from the NYSE and moved to the OTC Pink market.
• The company has suspended its SEC reporting obligations, reducing transparency for investors.

Risks

• The company has a history of net losses and expects to continue to incur operating losses.
• The delisting of the common stock and deregistration could further depress the securities market price and liquidity.
• The company will need additional funding and may not be able to raise capital when needed.
• The commercial success of the GentleWave System depends on market acceptance.
• The company faces competition from larger companies.
• The company depends on third-party suppliers, making it vulnerable to supply shortages and price fluctuations.
• The company's decision to deregister its common stock could negatively affect the liquidity and trading prices of its common stock, will result in substantially less disclosure about the company, and could severely impair its ability to raise capital.

Future Outlook

The company expects to continue to incur net losses for the next several years and will require additional financing to fund its operations and planned growth.

Industry Context

The document indicates that Sonendo operates in a competitive industry affected by new product introductions and activities of larger manufacturers and distributors like Dentsply Sirona, Envista, and Henry Schein. The company's success depends on factors such as acceptance by clinicians, patient outcomes, ease of use, and cost-effectiveness, as well as overcoming established treatment patterns.

Comparison to Industry Standards

• The document mentions competitors such as Dentsply Sirona, Envista, and Henry Schein, which are larger manufacturers and distributors in the dental device market.
• It states that many competitors have longer operating histories, greater name recognition, and more substantial financial, technical, marketing, sales, and distribution resources.
• The document does not provide specific comparisons of Sonendo's financial performance or metrics to those of its competitors, but it acknowledges that these competitors may have advantages due to their size and established market presence.

Management Changes

Legal Proceedings

• The company is involved in a legal proceeding filed by a former employee alleging violations of California wage and hour laws.

Stakeholder Impact

• Shareholders will experience reduced transparency and potentially lower liquidity due to the suspension of SEC reporting and trading on the OTC Pink market.
• Employees may face uncertainty due to cost-saving measures and potential restructuring.
• Customers may be affected by changes in product availability or support as the company navigates its financial challenges.
• Creditors are subject to the company's ability to meet its debt obligations and comply with loan covenants.

Next Steps

• The company intends to continue to commercialize its products.
• The company intends to explore financing options, including a combination of debt, equity, and non-dilutive sources.
• The company plans to pursue marketing authorizations and certifications in international markets.

Key Dates

Keywords

Sonendo, GentleWave System, root canal therapy, financial results, SEC reporting, delisting, OTC Pink, reverse stock split, debt amendment, Biolase, TDO Software, insurance reimbursement